SNEX

🔔Mid Day Trading Update🔔 📅Monday 18/7/2022📅 🟢Bullish Activity🟢 $APLS Up to a 3-month high this morning following news that the FDA has accepted and granted Priority Review designation of the New Drug Application for the company’s geographic atrophy treatment candidate (pegcetacoplan). The FDA said that it does not plan on holding an advisory committee meeting based on the Phase 2&3 data submitted and set a Prescription Drug User Fee Act target action date of November 26th, 2022. H.C. Wainwright initiated coverage on APLS with a Buy rating and put a $75.00 price target on the stock. The August 19th 60.00 call being the highest volume contract. $NVS Also to the upside after the Swiss drug maker reported Q2 earnings of $1.56 per share $0.06 beat on revenue that fell 1.4% YOY to $12.78B below the $12.80B consensus. The company forecasts that both full-year 2022 revenue and core operating income are expected to grow in the “mid-single digits”. The August 19th 90.00 call being the